IMMUNITYBIO, INC. Payments to Acquire Debt Securities, Available-for-sale
IMMUNITYBIO, INC. (IBRX) reported Payments to Acquire Debt Securities, Available-for-sale of $303.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $164.22M, a 990.34% increase year-over-year.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $139.09M, a 138993.00% increase year-over-year.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $45.63M, a 649.32% increase year-over-year.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $180.59M.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $241.37M, a 72.14% increase from fiscal 2024.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $140.22M, a 1253.72% increase from fiscal 2023.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $10.36M, a 69.81% decline from fiscal 2022.
- IMMUNITYBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $34.31M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $164.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $303.31M 10-Q · filed 2026-08-04 | $348.94M derived: sum of 3 quarters · filed 2026-08-04 | $529.52M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $139.09M 10-Q · filed 2026-05-07 | $184.72M derived: sum of 2 quarters · filed 2026-05-07 | $365.31M derived: sum of 3 quarters · filed 2026-05-07 | $380.37M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $45.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $226.21M derived: sum of 2 quarters · filed 2026-02-23 | $241.27M derived: sum of 3 quarters · filed 2026-08-04 | $241.37M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $180.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $195.65M derived: sum of 2 quarters · filed 2026-08-04 | $195.75M 10-Q · filed 2025-11-05 | $201.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $15.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $15.16M 10-Q · filed 2026-08-04 | $21.25M derived: sum of 3 quarters · filed 2026-08-04 | $21.25M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-07 | $6.19M derived: sum of 2 quarters · filed 2026-05-07 | $6.19M derived: sum of 3 quarters · filed 2026-05-07 | $91.95M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.09M derived: sum of 2 quarters · filed 2026-02-23 | $91.86M derived: sum of 3 quarters · filed 2026-02-23 | $140.22M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $85.77M derived: sum of 2 quarters · filed 2025-11-05 | $134.13M 10-Q · filed 2025-11-05 | $134.29M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | $85.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $134.13M 10-Q · filed 2025-08-05 | $134.29M derived: sum of 3 quarters · filed 2026-02-23 | $144.25M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $48.36M 10-Q · filed 2025-05-12 | $48.53M derived: sum of 2 quarters · filed 2026-02-23 | $58.48M derived: sum of 3 quarters · filed 2026-02-23 | $58.56M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $10.12M derived: sum of 2 quarters · filed 2026-02-23 | $10.20M derived: sum of 3 quarters · filed 2026-02-23 | $10.36M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $9.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $10.03M derived: sum of 2 quarters · filed 2024-11-12 | $10.19M 10-Q · filed 2024-11-12 | $10.21M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $236.00K 10-Q · filed 2024-08-12 | $255.00K derived: sum of 3 quarters · filed 2025-03-03 | $341.00K derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $158.00K 10-Q · filed 2024-05-09 | $177.00K derived: sum of 2 quarters · filed 2025-03-03 | $263.00K derived: sum of 3 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $105.00K derived: sum of 2 quarters · filed 2025-03-03 | $34.31M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $34.29M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $34.21M 10-Q · filed 2023-08-08 | ||||
| 2020-12-31 | $6.18M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $76.97M derived: sum of 2 quarters · filed 2021-04-22 | $81.47M derived: sum of 3 quarters · filed 2021-04-22 | $91.77M 8-K/A · filed 2021-04-22 | $91.57M 10-K · filed 2021-03-04 |
| 2020-09-30 | $70.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $75.28M derived: sum of 2 quarters · filed 2020-11-09 | $85.58M 10-Q · filed 2020-11-09 | $95.94M derived: sum of 4 quarters · filed 2021-04-22 | |
| 2020-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $14.79M 10-Q · filed 2020-08-07 | $25.15M derived: sum of 3 quarters · filed 2021-04-22 | $35.19M derived: sum of 4 quarters · filed 2021-04-22 | |
| 2020-03-31 | $10.30M 10-Q · filed 2020-05-11 | $20.66M derived: sum of 2 quarters · filed 2021-04-22 | $30.70M derived: sum of 3 quarters · filed 2021-04-22 | $47.22M derived: sum of 4 quarters · filed 2021-04-22 | |
| 2019-12-31 | $10.36M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $20.40M derived: sum of 2 quarters · filed 2021-04-22 | $36.92M derived: sum of 3 quarters · filed 2021-04-22 | $87.19M 8-K/A · filed 2021-04-22 | $86.62M 10-K · filed 2020-03-25 |
| 2019-09-30 | $10.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $26.56M derived: sum of 2 quarters · filed 2020-11-09 | $76.83M 10-Q · filed 2020-11-09 | $89.34M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $16.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $66.79M 10-Q · filed 2020-08-07 | $79.30M derived: sum of 3 quarters · filed 2021-03-04 | $108.06M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | $50.27M 10-Q · filed 2020-05-11 | $62.79M derived: sum of 2 quarters · filed 2021-03-04 | $91.54M derived: sum of 3 quarters · filed 2021-03-04 | $113.00M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2018-12-31 | $12.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $41.27M derived: sum of 2 quarters · filed 2021-03-04 | $62.73M derived: sum of 3 quarters · filed 2021-03-04 | $94.77M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $28.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $50.22M derived: sum of 2 quarters · filed 2019-11-05 | $82.26M 10-Q · filed 2019-11-05 | $118.50M derived: sum of 4 quarters · filed 2020-03-25 | |
| 2018-06-30 | $21.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $53.50M 10-Q · filed 2019-08-06 | $89.74M derived: sum of 3 quarters · filed 2020-03-25 | $118.34M derived: sum of 4 quarters · filed 2020-03-25 | |
| 2018-03-31 | $32.04M 10-Q · filed 2019-05-08 | $68.28M derived: sum of 2 quarters · filed 2020-03-25 | $96.88M derived: sum of 3 quarters · filed 2020-03-25 | ||
| 2017-12-31 | $36.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $64.84M derived: sum of 2 quarters · filed 2020-03-25 | $111.36M 10-K · filed 2020-03-25 | ||
| 2017-09-30 | $28.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $75.11M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $46.52M 10-Q · filed 2018-08-06 | ||||
| 2016-12-31 | $273.00M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |